Related Experiment Videos
Treatment with locally applied mitoxantrone
1Medizinischen Klinik II für Hämatologie, Onkologie und Immunologle, St. Johannes-Hospital, Duisburg, FRG.
Abstract:
In 30 patients mitoxantrone was administered via an intracavitary route intraperitoneally, intrapleurally or intrapericardially. From 13 patients with malignant pleural effusion 5 showed a complete and 3 a partial remission. 2 of 2 patients with pericardial effusion showed a complete remission. From 16 patients with peritoneal carcinosis 4 showed a complete and 3 a partial remission.
Insights
Intracavitary mitoxantrone showed promise in treating malignant effusions and peritoneal carcinosis. This approach led to complete or partial remission in a significant number of patients with these advanced cancers.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant effusions and peritoneal carcinosis are advanced stages of cancer.
- Intracavitary chemotherapy offers a targeted approach to localized cancer spread.
Purpose of the Study:
- To evaluate the efficacy of intracavitary mitoxantrone in patients with malignant pleural effusion, pericardial effusion, and peritoneal carcinosis.
Main Methods:
- Mitoxantrone was administered intracavitary (intraperitoneally, intrapleurally, or intrapericardially) to 30 patients.
- Response was assessed based on complete and partial remission rates.
Main Results:
- In malignant pleural effusion (13 patients): 5 complete and 3 partial remissions.
- In pericardial effusion (2 patients): 2 complete remissions.
- In peritoneal carcinosis (16 patients): 4 complete and 3 partial remissions.
Conclusions:
- Intracavitary mitoxantrone demonstrates significant efficacy in managing malignant effusions and peritoneal carcinosis.
- This administration route provides a viable treatment option for localized cancer recurrence.